This is supported by the evidence that silencing IL-6 and thrombopoietin abrogates thrombocytosis in animal models (16), and pre-treatment thrombocytosis in patients with EOC tends to be related to advanced stage, higher grade, higher level of CA-125, larger ascites volume, and larger tumor residual (31–35). The gene discussed is IL6; the disease is neoplasm.